The Progress of Checkpoint Inhibitors in Melanoma Treatment
DOI:
https://doi.org/10.54097/9x4ce244Keywords:
Checkpoint Inhibitors, Melanoma, Treatment.Abstract
Melanoma is a type of skin cancer that is considered aggressive and with high metastatic capabilities. The invention of checkpoint inhibitors has revolutionized the approaches to treating melanoma by enhancing anti-tumor immunity and improving survival rates for patients. The first checkpoint inhibitor was approved by the FDA in 2011, targeting CTLA-4 and PD-1, and has shown promising response and provided better quality of life compared to traditional therapies such as chemotherapies. On the other hand, the clinical usage of checkpoint inhibitors is hindered by the development of resistance and immune-related toxicities. Researchers are focusing on novel checkpoint targets that could potentially overcome the current challenges, such as LAG-3 and TIGIT, which can restore cytotoxic T-cell function and enhance immune surveillance. These next-generational immunotherapy targets embrace the potential to achieve more durable control of melanoma while reducing adverse effects and resistance, marking a next step toward a more effective cancer treatment for melanoma.
Downloads
References
[1] Heistein, J. B., Acharya, U., & Mukkamalla, S. K. R. (2024, February 17). Malignant melanoma. In StatPearls. StatPearls Publishing.
[2] Surveillance, Epidemiology, and End Results (SEER) Program. (n.d.). Cancer stat facts: Melanoma of the skin. National Cancer Institute.
[3] Buchbinder, E. I., & Desai, A. (2016). CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. American Journal of Clinical Oncology
[4] CiRen, B., Wang, X., & Long, Z. (2016). The evaluation of immunotherapy and chemotherapy treatment on melanoma: A network meta-analysis. Oncotarget
[5] Perez, L., Samlowski, W., & Lopez-Flores, R. (2022). Outcome of elective checkpoint inhibitor discontinuation in melanoma patients with complete remission. Biomedicines
[6] Wang, D. Y., Eroglu, Z., Ozgun, A., Leger, P. D., Zhao, S., Ye, F., Luke, J. J., Joseph, R. W., Haq, R., Ott, P. A., Hodi, F. S., Sosman, J. A., Johnson, D. B., & Buchbinder, E. I. (2017). Clinical features of acquired resistance to anti–PD-1 therapy in advanced melanoma. Cancer Immunology Research
[7] Zielińska, M. K., Ciążyńska, M., Sulejczak, D., Rutkowski, P., & Czarnecka, A. M. (2025). Mechanisms of resistance to anti-PD-1 immunotherapy in melanoma and strategies to overcome it. Biomolecules
[8] Schonfeld, S. J., Tucker, M. A., Engels, E. A., Dores, G. M., Sampson, J. N., Shiels, M. S., Chanock, S. J., & Morton, L. M. (2022). Immune-related adverse events after immune checkpoint inhibitors for melanoma among older adults. JAMA Network Open
[9] Wang, S. J., Dougan, S. K., & Dougan, M. (2023). Immune mechanisms of toxicity from checkpoint inhibitors. Trends in Cancer
[10] Mireștean, C. C., Iancu, R. I., & Iancu, D. P. T. (2025). LAG3, TIM3 and TIGIT: New targets for immunotherapy and potential associations with radiotherapy. Current Oncology
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Academic Journal of Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
